IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 for the treatment of patients with multiple myeloma.
We believe that IGM-2644 with its 10 binding units for CD38 may bind to CD38 expressing cancer cells more strongly (higher avidity) than an IgG bispecific antibody with only one or two binding units for CD38. This may enhance efficacy in patients that develop resistance to anti-CD38 IgG antibodies due to downregulation of CD38. In addition to T cell mediated cytotoxicity, IGM-2644 can also induce complement mediated cytotoxicity which may induce cancer cell death in the absence of T cells.
IGM-2644 is also being considered for use in the treatment of autoimmune diseases given that CD38 is expressed on plasma cells which are the source of autoreactive antibodies in several autoimmune diseases.
We are conducting a Phase 1 clinical trial of IGM-2644 in multiple myeloma.